DEA DIVERSION THE NEW PHARMACEUTICAL ROADBLOCK: Take the case of MMJ's Cannabis Drug Development
Press Release

DEA DIVERSION THE NEW PHARMACEUTICAL ROADBLOCK: Take the case of MMJ's Cannabis Drug Development

The DEA Diversion Control Problem: A Hidden Threat to U.S. Pharmaceutical Manufacturing ?

Take the case of MMJ BioPharma Cultivation - despite submissions of FDA Investigational New Drug (IND) applications and Orphan Drug Designation approval for treating Huntington's Disease - has been blocked from manufacturing cannabis-derived pharmaceuticals by the DEA, under the leadership of Deputy Administrator Thomas Prevoznik.

Read More